MATHEMATICAL FORMULA WITH FLOATING VARIABLE FOR PROGNOSIS OF SURVIVAL AND PERSONIFICATION OF PROGRAMS OF INTEGRATED TREATMENT OF PATIENTS WITH CANCER OF STOMACH

In this paper, we illustrate the possibilities of modern online tools for mathematical computations of linear equation analysis systems and show a detailed algorithm a was done for a group of patients with stomach cancer (n = 221). Using the construction of a 9-variable system that is simple enough to understand, specific factors have been established that formed the formula for calculating the survival rate of gastric cancer patients operated radically in the Odessa Regional Oncology Dispensary in the period 2007–2013. Survival of this group of patients was calculated using the computer program "Regional Cancer Registry". The role in the survival of patients of such factors as the degree of primary tumor differentiation, the expression of TP53oncoprotein, the degree of infiltration of stomach wall from T1 = 1 toT4a = 4, T4b = 5, the number of regional lymph nodes in which metastases are found, measured by a morphologist after removal and some other factors.

Download Full-text

Nuclear morphometry for the prediction of regional lymph nodes metastases in patients with cancer of the larynx

Otolaryngology ◽

10.1067/mhn.2000.111291 ◽

2000 ◽

Vol 123 (6) ◽

pp. 770-774 ◽

Cited By ~ 2

Author(s):

Wiesław Dobroś ◽

Krzysztof Gil ◽

Janusz Ryś ◽

Krystyna Stanisz-Wallis

Keyword(s):

Lymph Nodes ◽

Regional Lymph Nodes ◽

Patients With Cancer ◽

Nuclear Morphometry ◽

Lymph Nodes Metastases

Download Full-text

HER-2 Expression in Immunohistochemistry Has No Prognostic Significance in Gastric Cancer Patients

The Scientific World JOURNAL ◽

10.1100/2012/941259 ◽

2012 ◽

Vol 2012 ◽

pp. 1-6 ◽

Cited By ~ 23

Author(s):

Agnieszka Halon ◽

Piotr Donizy ◽

Przemyslaw Biecek ◽

Julia Rudno-Rudzinska ◽

Wojciech Kielan ◽

...

Keyword(s):

Gastric Cancer ◽

Test Score ◽

Prognostic Significance ◽

Clinicopathological Parameters ◽

Prognostic Impact ◽

Curative Surgery ◽

Regional Lymph Nodes ◽

Poorly Differentiated ◽

Her 2 ◽

Gastric Cancer Patients

The role of HER-2 expression as a prognostic factor in gastric cancer (GC) is still controversial. The aim of the study was to asses HER-2 status, its correlations with clinicopathological parameters, and prognostic impact in GC patients. Tumor samples were collected from 78 patients who had undergone curative surgery. In order to evaluate the intensity of immunohistochemical (IHC) reactions two scales were applied: the immunoreactive score according to Remmele modified by the authors and standardised Hercep test score modified for GC by Hofmann et al. The HER-2 overexpression was detected by IHC in 23 (29.5%) tumors in Hercep test (score 2+/3+) and in 24 (30.7%) in IRS scale (IRS 4–12). The overexpression of HER-2 was associated with poorly differentiated tumors, but this correlation was not significant (P=0.064). No relationship was found between HER-2 expression and primary tumor size and degree of spread to regional lymph nodes. Both univariate and multivariate analyses revealed that TNM stage and patient’s age were the crucial negative prognostic factors. No correlation was observed between patient survival and expression of HER-2 estimated using both scales. This research did not confirm HER-2 expression (evaluated with immunohistochemistry) value as a prognostic tool in GC.

Download Full-text

The Impact of COVID-19 on Gastric Cancer Surgery: A Single-Center Retrospective Study

10.21203/rs.3.rs-35676/v3 ◽

2020 ◽

Author(s):

Yu-xuan Li ◽

Chang-zheng He ◽

Yi-chen Liu ◽

Peng-yue Zhao ◽

Xiao-lei Xu ◽

...

Keyword(s):

Gastric Cancer ◽

Waiting Time ◽

World Health ◽

Abdominal Ct ◽

Surgical Strategies ◽

Patients With Cancer ◽

Global Pandemic ◽

Health Organization ◽

Gastric Cancer Patients ◽

The Impact

Abstract Background: The coronavirus disease 2019 (COVID-19) has been declared a global pandemic by the World Health Organization. Patients with cancer are more likely to incur poor clinical outcomes. Due to the prevailing pandemic, we propose some surgical strategies for gastric cancer patients. Methods: The ‘COVID-19’ period was defined as occurring between 2020-01-20 and 2020-03-20. The enrolled patients were divided into two groups, pre-COVID-19 group (PCG) and COVID-19 group (CG). A total of 109 patients with gastric cancer were enrolled in this study. Results: The waiting time before admission increased by 4 days in the CG (PCG: 4.5 [IQR: 2, 7.8] vs. CG: 8.0 [IQR: 2,20]; p=0.006). More patients had performed chest CT scans besides abdominal CT before admission during the COVID-19 period (PCG: 22 [32%] vs. CG: 30 [73%], p=0.001). After admission during the COVID period, the waiting time before surgery was longer (PCG: 3[IQR: 2,5] vs. CG: 7[IQR: 5,9]; p<0.001), more laparoscopic surgeries were performed (PCG: 51[75%] vs. CG: 38[92%], p=0.021), and hospital stay period after surgery was longer (7[IQR: 6,8] vs.9[IQR:7,11]; p<0.001). In addition, the total cost of hospitalization increased during this period, (PCG: 9.22[IQR:7.82,10.97] vs. CG: 10.42[IQR:8.99,12.57]; p=0.006). Conclusion: This study provides an opportunity for our surgical colleagues to reflect on their own services and any contingency plans they may have to tackle the COVID-19 crisis.

Download Full-text

Upper Extremity Venous Thrombosis in Patients With Cancer With Peripherally Inserted Central Venous Catheters: A Retrospective Analysis of Risk Factors

Journal of Oncology Practice ◽

10.1200/jop.2012.000595 ◽

2013 ◽

Vol 9 (1) ◽

pp. e8-e12 ◽

Cited By ~ 26

Author(s):

Daniel H. Ahn ◽

Henrik Bo Illum ◽

David H. Wang ◽

Anant Sharma ◽

Jonathan E. Dowell

Keyword(s):

Risk Factors ◽

Protective Effect ◽

Venous Thrombosis ◽

Retrospective Analysis ◽

Upper Extremity ◽

Central Venous Catheters ◽

Central Venous ◽

Patients With Cancer ◽

Specific Factors

Specific factors significantly increase the risk of upper extremity venous thrombosis in patients with cancer with PICCs, whereas use of anti-platelet agents seems to have a protective effect against it.

Download Full-text

Thrombosis and Cancer: Emerging Data for the Practicing Oncologist

American Society of Clinical Oncology Educational Book ◽

10.14694/edbook_am.2013.33.e337 ◽

2013 ◽

pp. e337-e345 ◽

Cited By ~ 3

Author(s):

Gary H. Lyman ◽

Alok A. Khorana ◽

Anna Falanga

Keyword(s):

Risk Factors ◽

Clinical Practice ◽

Venous Thromboembolism ◽

Practice Guidelines ◽

Malignant Disease ◽

Patients With Cancer ◽

Treatment And Prevention ◽

Close Relationship ◽

Specific Factors ◽

American Society

The American Society of Clinical Oncology (ASCO) recently updated clinical practice guidelines on the treatment and prevention of venous thromboembolism (VTE) in patients with cancer. Although several new studies have been reported, many questions remain about the close relationship between VTE and malignant disease. The risk of VTE among patients with cancer continues to increase and is clearly linked to patient-, disease- and treatment-specific factors. In general, VTE among patients with cancer is treated in a similar fashion to that in other patient populations. However, the greater risk of VTE in patients with cancer, the multitude of risk factors, and the greater risk of VTE recurrence and mortality among patients with cancer pose important challenges for surgeons, oncologists, and other providers.

Download Full-text

Senescence as a Dictator of Patient Outcomes and Therapeutic Efficacies in Human Gastric Cancer

10.21203/rs.3.rs-855919/v1 ◽

2021 ◽

Author(s):

Qiang Sun ◽

Lulin Zhou ◽

Zubiao Niu ◽

Yuqi Wang ◽

You Zheng ◽

...

Keyword(s):

Gastric Cancer ◽

Patient Outcomes ◽

Gene Signature ◽

Human Gastric Cancer ◽

Free Survival ◽

Patients With Cancer ◽

Signature Genes ◽

Multiple Datasets ◽

Gastric Cancer Patients ◽

Cancerous Cells

Abstract Senescence is believed to be a pivotal player in the onset and progression of tumors as well as cancer therapy. However, the guiding roles of senescence in clinical outcomes and therapy selection for patients with cancer remains obscure, largely due to the absence of a feasible senescence signature. Here, by integrative analysis of single cell and bulk transcriptome data from multiple datasets of gastric cancer patients, we uncovered senescence as a veiled tumour feature characterized by senescence gene signature enriched, unexpectedly, in the non-cancerous cells, and further identified two distinct senescence-associated subtypes based on the unsupervised clustering. Patients with the senescence subtype had higher tumor mutation loads and better prognosis as compared with the aggressive subtype. By the machine learning, we constructed a scoring system termed as senescore based on 6 signature genes: ADH1B, IL1A, SERPINE1, SPARC, EZH2 and TNFAIP2. Higher senescore demonstrated robustly predictive capability for longer overall and recurrence-free survival in 2290 gastric cancer samples, which was independently validated by the multiplex staining analysis of gastric cancer samples on the tissue microarray. Remarkably, the senescore signature served as a reliable predictor of chemo- and immuno-therapeutic efficacies, with high-senescore patients benefited from immunotherapy while low-senescore patients were responsive to chemotherapy. Collectively, we report senescence as a heretofore unrecognized hallmark of gastric cancer that impacts patient outcomes and therapeutic efficacy.

Download Full-text

The Impact of COVID-19 on Gastric Cancer Surgery: A Single-center Retrospective Study Based on Real-world Data from China

10.21203/rs.3.rs-35676/v1 ◽

2020 ◽

Author(s):

Yu-xuan Li ◽

Chang-zheng He ◽

Yi-chen Liu ◽

Peng-yue Zhao ◽

Xiao-lei Xu ◽

...

Keyword(s):

Gastric Cancer ◽

Cancer Patients ◽

Waiting Times ◽

Cancer Surgery ◽

Real World Data ◽

Gastric Cancer Surgery ◽

Patients With Cancer ◽

Study Results ◽

Gastric Cancer Patients ◽

The Impact

Abstract Backgrounds: A respiratory epidemic defined as coronavirus disease 2019 (COVID-19) is becoming unstoppable and has been declared a pandemic. Patients with cancer are more likely to develop COVID-19. Based on our experience during the pandemic period, we propose some surgery strategies for gastric cancer patients under the COVID-19 situation. Methods We defined the ‘COVID-19’ period as occurring between 2020-01-20 and 2020-03-20. All the enrolled patients were divided into two groups, pre-COVID-19 group (PCG) and COVID-19 group (CG). A total of 109 patients with gastric cancer were enrolled in this study. Results The waiting times before admission increased by 4 days in CG(PCG:4.5 [IQR: 2, 7.8] vs. CG:8.0 [IQR: 2,20]; P = 0.006). More patients had performed chest CT scan besides abdominal CT before admission during COVID-19 period(PCG:22[32%]vs. CG:30[73%], p = 0.001). After admission, during COVID period, the waiting time before surgery was longer(3[IQR: 2,5] vs. 7[IQR: 5,9]; P < 0.001),more laparoscopic surgery were performed(PCG: 51[75%] vs. CG: 38[92%],p = 0.021), and hospital stay after surgery was longer (7[IQR: 6,8] vs.9[IQR:7,11] ; P < 0.001). The total cost of hospitalization increased during COVID period, (9.22[IQR:7.82,10.97] vs. 10.42[IQR:8.99,12.57]; p = 0.006). Conclusion Since no data is available yet on the impact of COVID-19 on gastric cancer patients,our own experience with COVID-19 in gastric cancer surgery has hopefully provided an opportunity for colleagues to reflect on their own service and any contingency plans they have to tackle the crisis.

Download Full-text

The impact of COVID-19 on gastric cancer surgery: a single-center retrospective study

BMC Surgery ◽

10.1186/s12893-020-00885-7 ◽

2020 ◽

Vol 20 (1) ◽

Author(s):

Yu-xuan Li ◽

Chang-zheng He ◽

Yi-chen Liu ◽

Peng-yue Zhao ◽

Xiao-lei Xu ◽

...

Keyword(s):

Gastric Cancer ◽

Waiting Time ◽

World Health ◽

Abdominal Ct ◽

Surgical Strategies ◽

Patients With Cancer ◽

Global Pandemic ◽

Health Organization ◽

Gastric Cancer Patients ◽

The Impact

Abstract Background The coronavirus disease 2019 (COVID-19) has been declared a global pandemic by the World Health Organization. Patients with cancer are more likely to incur poor clinical outcomes. Due to the prevailing pandemic, we propose some surgical strategies for gastric cancer patients. Methods The ‘COVID-19’ period was defined as occurring between 2020 and 01-20 and 2020-03-20. The enrolled patients were divided into two groups, pre-COVID-19 group (PCG) and COVID-19 group (CG). A total of 109 patients with gastric cancer were enrolled in this study. Results The waiting time before admission increased by 4 days in the CG (PCG: 4.5 [IQR: 2, 7.8] vs. CG: 8.0 [IQR: 2,20]; p = 0.006). More patients had performed chest CT scans besides abdominal CT before admission during the COVID-19 period (PCG: 22 [32%] vs. CG: 30 [73%], p = 0.001). After admission during the COVID period, the waiting time before surgery was longer (PCG: 3[IQR: 2,5] vs. CG: 7[IQR: 5,9]; p < 0.001), more laparoscopic surgeries were performed (PCG: 51[75%] vs. CG: 38[92%], p = 0.021), and hospital stay period after surgery was longer (7[IQR: 6,8] vs.9[IQR:7,11]; p < 0.001). In addition, the total cost of hospitalization increased during this period, (PCG: 9.22[IQR:7.82,10.97] vs. CG: 10.42[IQR:8.99,12.57]; p = 0.006). Conclusion This study provides an opportunity for our surgical colleagues to reflect on their own services and any contingency plans they may have to tackle the COVID-19 crisis.

Download Full-text

Prognostic outcome of gastric cancer patients with cancer stem cell SNPs in Asian versus western countries.

Journal of Clinical Oncology ◽

10.1200/jco.2013.31.15_suppl.4110 ◽

2013 ◽

Vol 31 (15_suppl) ◽

pp. 4110-4110

Author(s):

Melissa Janae Labonte ◽

Takeru Wakatsuki ◽

Wu Zhang ◽

Dongyun Yang ◽

Mizutomo Azuma ◽

...

Keyword(s):

Gastric Cancer ◽

Regional Differences ◽

Prognostic Role ◽

Direct Dna Sequencing ◽

Western Countries ◽

Patients With Cancer ◽

Japanese Cohort ◽

The Us ◽

Gastric Cancer Patients

4110 Background: The clinical significance of cancer stem cells (CSC) has been well established; however, its prognostic role remains controversial. CD44 is recognized as a CSC marker in gastric cancer (GC) and, recently, the clinical impact of CD166 in GC was reported. Our group previously reported SNPs of CD44 and CD166 are associated with outcome in US patients (pts) with adjuvant GC and colorectal cancer, respectively. Since GC has regional differences in epidemiology and clinicopathology, we hypothesized that ethnicity and regional differences in GC could influence the prognostic role of CD44 and CD166. Methods: A total of 369 pts with histopathologically-confirmed localized (stage Ib to IV; AJCC-6th) GC were enrolled from Japan (n=169), the US (n=137), and Austria (n=63) between 2002 and 2010. CD44 rs187116 G>A and CD166 rs1157 G>A were analyzed. Genomic DNA was extracted from blood or tissue, and all samples were analyzed by PCR-based direct DNA-sequencing. Results: Pts homozygous for A/A CD44rs187116 (n=20) showed a median OS of 2.0 yrs vs not reached for patients harboring at least one-G allele (n=144) (HR: 2.87 [95%CI: 1.61-5.13], p<0.001) in Japanese cohort, while pts homozygous A/A (n=30) showed a median OS of 7.3 yrs vs 4.1 yrs for pts harboring at least one-G allele (n=94) (HR: 2.0 [95%CI: 0.90-4.55], p=0.079) in the US cohort. There were no significant differences in Austrian cohort alone or in combination with US cohort. In CD166 rs1157, pts harboring at least one-A allele (n=27) showed a median OS of 3.9 yrs vs not reached for pts homozygous G/G (n=142) (HR: 1.81 [95%CI: 1.05-3.12], p=0.033) in Japanese cohort., Although there were no significant differences in the US or Austrian cohort when analyzed separately, combining cohorts demonstrated that pts homozygous A/A (n=12) showed a median OS of not reached yrs vs 4.7 yrs for pts harboring at least one-G allele (n=179) (HR: 5.00 [95%CI: 0.70-35.95], p=0.073). Conclusions: SNP profiles in CSC markers predicted opposite prognostic outcomes in patients with GC among Asian and Western countries. This is the first report suggesting that the prognostic role of CSC markers in GC may differ based on ethnic groups or etiology differences.

Download Full-text